{"cluster": 50, "subcluster": 28, "abstract_summ": "Even today, many hemophilia patients and their families still retain painful and indelible memories of HIV and hepatitis C infections or are confronted with the progressive health consequences of these infections.Over the past few decades, several blood-borne viruses have targeted hemophilia patients requiring treatment with clotting factors derived from human plasma [1].Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.Yet, blood products are important sources of HIV infection in low- and middle-income nations.Convalescent plasma therapy holds promise as a transient treatment for COVID-19.", "title_summ": "Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemicThe COVID-19 Pandemic: New Global Challenges for the Hemophilia Community.COVID\u201019: Moving beyond the pandemic", "title_abstract_phrases": "Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemicConvalescent plasma therapy holds promise as a transient treatment for COVID-19.Over the past few decades, several blood-borne viruses have targeted hemophilia patients requiring treatment with clotting factors derived from human plasma [1].Even today, many hemophilia patients and their families still retain painful and indelible memories of HIV and hepatitis C infections or are confronted with the progressive health consequences of these infections.Great care must be taken to prevent plasma therapy from fueling HIV epidemics in the developing world.Yet, blood products are important sources of HIV infection in low- and middle-income nations."}